X.T.L. Biopharmaceuticals Ltd ADR(XTLB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 4:10 PM ET (Korea 10/1 05:10)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 2.46% | Shs Outstand | 4.2M | Perf Week | 9.09% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 4.1M | Perf Month | -3.61% |
| Enterprise Value | - | PEG | - | EPS next Q | - | Inst Own | 0.18% | Short Float | 0.17% | Perf Quarter | -3.61% |
| Income | - | P/S | - | EPS this Y | - | Inst Trans | -99.8% | Short Ratio | 0.1 | Perf Half Y | -0.41% |
| Sales | - | P/B | - | EPS next 5Y | - | ROA | - | Short Interest | 0.01M | Perf YTD | 3.45% |
| Book/sh | - | P/C | - | EPS past 3/5Y | 29.65% 31.74% | ROE | - | 52W High | -76.65% ($10.28) | Perf Year | -48.72% |
| Cash/sh | - | P/FCF | - | Sales past 3/5Y | - | ROIC | - | 52W Low | 19.4% ($2.01) | Perf 3Y | -33.16% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 65.58% | Gross Margin | - | Volatility(W/M) | 9.98% 7.23% | Perf 5Y | -86.3% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.19 | Perf 10Y | -87.37% |
| Dividend Ex-Date | - | Quick Ratio | - | EPS Q/Q | 44.39% | Profit Margin | - | RSI (14) | 47.49 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | - | Sales Q/Q | - | SMA20 | -0.68% ($2.42) | Beta | 1.38 | Target Price | $6 |
| Payout | - | Debt/Eq | - | Earnings | - | SMA50 | -9.87% ($2.66) | Rel Volume | 0.02 | Prev Close | $2.21 |
| Employees | 6 | LT Debt/Eq | - | EPS/Sales Surpr. | - | SMA200 | -15.46% ($2.84) | Avg Volume(3M) | 0.07M | Price | $2.4 |
| IPO | 2005/9/1 | Option/Short | No/Yes | Trades | 29 | Volume | 1,564 | Change | 8.6% |
🧪 This Israel-based clinical-stage biotech company focuses on autoimmune diseases and hematologic cancers. Its lead candidate, hCDR1, is preparing to enter Phase 2 clinical trials for systemic lupus erythematosus (SLE) and Sjögren's syndrome, while rHuEPO is also being developed to extend survival in multiple myeloma patients. The micro-cap stock is dual-listed on the U.S. Nasdaq and the Tel Aviv Stock Exchange.
Over the past 1 year, on the lower side
77% below its 1-year high.
Traded less than usual That is 2% of its average volume.
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -86.3%. The S&P 500 did +78% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.2%.
Tap to view numbers
It ranks #510 of 592 in the industry
Based on market cap of $10M.
MTVA#507 MetaVia Inc $10M PER - 
TOVX#508 Theriva Biologics Inc $10M PER - 
MBRX#509 Moleculin Biotech Inc $10M PER - XTLB#510 X.T.L. Biopharmaceuticals Ltd ADR $10M PER - 
GDTC#511 CytoMed Therapeutics Ltd $10M PER - 
FAQ
What kind of company is XTLB?
XTLB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XTLB?
The market cap of XTLB is approximately $10M, ranking 5,481 within its sector.
What is the 52-week high and low for XTLB?
XTLB has recorded a 52-week high of $10.28 and a low of $2.01.
